Home > News > 48/Validation of a data-driven biomarker model for atrial fibrillation in an unselected community-based patient cohort presenting acutely to hospital
Atrial Fibrillation
Read Time: 2 mins

48/Validation of a data-driven biomarker model for atrial fibrillation in an unselected community-based patient cohort presenting acutely to hospital

Published Online: October 4th 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr48
Authors: W Chua (Presenting Author) – University of Birmingham, Birmingham, UK; VR Cardoso – University of Birmingham, Birmingham, UK; GV Gkoutos – University of Birmingham, Birmingham, UK; P Kastner – Roche Diagnostics GMBH, Penzberg, Germany; H Mahmood – Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK; Neculau – Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK; Y Purmah – University of Birmingham, Birmingham, UK; K Russell – Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK; SP Tull – University of Birmingham, Birmingham, UK; A Turner – Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK; A Ziegler – Roche Diagnostics International AG, Rotkreuz, Switzerland; L Fabritz – University of Birmingham, Birmingham, UK; P Kirchhof – University of Birmingham, Birmingham, UK
Quick Links:
Article
Article Information
Article:

Background/Introduction: Atrial fibrillation (AF) is a common condition in patients presenting acutely to hospital. A simple model which could be applied as a point-of-care test could screen for patients needing referral for diagnostic testing or identify patients with asymptomatic AF. A model incorporating simple clinical characteristics and blood biomarkers has previously been developed using robust data-driven statistical and machine learning methodologies. Here, we validate the model using data not included in model development.

Methods: We quantified plasma levels of two protein biomarkers which were previously identified as associated with prevalent AF (N-terminal prohormone of brain natriuretic peptide, NTproBNP, and fibroblast growth factor 23, FGF23) in patients presenting to a large teaching hospital. This study is part of the Birmingham and Black Country Atrial Fibrillation Registry (BBC-AF). Data from these patients were fitted to the previously derived model (age, sex, BMI, BNP, FGF23). Adjustments to the data were made to accommodate differences in biomarkers quantified (BNP versus NTproBNP) and measurement platforms (versus Roche Diagnostics). The model’s performance was quantified by the C-statistic and 95% confidence intervals (CI).

Results: Overall, 1,089 patients (46% with AF; mean [standard deviation] age 69 [12] years old, 59% males, mean [SD] BMI 29.52 [6.63] kg/m2) were included in the analysis. As the model was developed using BNP, NTproBNP values were adjusted by a factor of three to approximate the known ratio of circulating proteins based on literature. NTproBNP and FGF23 values were also converted to the Log2 scale to align with the nature of the data used for model development. Patients with AF were older (mean [SD] 72 [11]; without AF 66 [12]), and had significantly elevated levels of both NTproBNP (mean [SD] 8.53 [2.25] Log2pg/mL, without AF 7.19 [2.49] Log2pg/mL; p<0.001; Figure 1a) as well as FGF23 (median [IQR] 7.59 [7.03–8.70] Log2pg/mL, without AF 7.27 [6.71–8.03] Log2pg/mL, p<0.001; Figure 1b). The model yielded a C-statistic of 0.689 (95% CI 0.658, 0.721; Figure 1c) which is a reasonable fit in comparison to the original model which had a C-statistic of 0.691 (95% CI 0.638, 0.744), considering the expected overfitting in model development.

Conclusions: We developed a model incorporating three simple clinical risk factors (age, sex, and BMI) and two biomarkers (BNP and FGF-23) to identify patients with AF. The model performed well in a validation with data not used for model development. The model was robust despite known biological differences between BNP and NTproBNP, as well as being measured on different quantification platforms. We call for further external validation in other heterogenous cohorts.

 

Article Information:

Further Resources

Share this Article
Related Content In Atrial Fibrillation
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72